Oragenics OGEN 深 滬
已收盤 08-07 16:00:00 美东时间
0.5499
+0.006
+1.18%
華盛通- 最 高0.551
- 今 開0.55
- 成交量 1.39万股
- 最 低 0.5377
- 昨 收 0.5435
- 總市值 248.11万
- 52周最高 1.45
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 0.4801
- 委 比 0.00%
- 總股本 451.20万
- 歷史最高 83700.00
- 量 比 0.50
- 振 幅 2.45%
- 歷史最低 0.4801
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oragenics Highlights Investor Outreach at Micro-Cap Conference
The latest update is out from Oragenics ( ($OGEN) ). On May 18, 2026, Oragenics...
05-19 20:58
Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY
Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increase over losses of $(3.60) per share from the same period last year.
05-09 06:14
Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierSarasota, FL and San Diego, CA, May 07,
05-07 20:34
Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage
04-20 21:04
Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
04-13 20:34
Oragenics Sets New 2025 Annual Shareholder Meeting Date
The latest update is out from Oragenics ( ($OGEN) ). On March 27, 2026, Orageni...
04-01 07:45
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Oragenics, Inc. announced that its audited consolidated financial statements for the year ended December 31, 2025, include an unqualified audit opinion with a going concern explanatory paragraph. The Annual Report on Form 10-K, filed on March 16, 2026, is available on the SEC's EDGAR system and the company's investor relations website. The company specializes in brain-targeted therapeutics via proprietary intranasal delivery technology, focusing ...
03-25 22:30
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Oragenics, Inc. reported significant progress in 2025, transitioning to a focused biotech company with key milestones including NYSE compliance, clinical trial advancements, manufacturing shift to the U.S., and AI partnerships. The company raised $16.5 million, repaid debt, and reduced expenses. In early 2026, they secured ethics approval, initiated trial sites, and prepared for U.S. clinical activities. Priorities for 2026 include completing Pha...
03-17 12:30
